Tonafil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tonafil

Property Description
Active ingredient Sildenafil
Form Film-coated tablet
Pharmacological class Phosphodiesterase type 5 (PDE5) inhibitor
Common use (Agent Class) Agent for localized blood flow support
Origin Synthetic compound

Tonafil: Its Identity, Composition, and Origin

Tonafil is a synthetic, prescription-only medication whose active component is Sildenafil. It is most commonly manufactured as an oral film-coated tablet, a solid preparation designed for ingestion. This preparation ensures that Tonafil delivers a precise quantity of its single active ingredient, Sildenafil, which is utilized in the form of Sildenafil citrate. The synthetic origin of the compound guarantees high purity and pharmacological consistency, a crucial factor for a medication designed to modulate sensitive physiological functions through oral therapy.

What Type of Drug is Tonafil? (Pharmacological Class and Purpose)

Tonafil belongs to the highly specific pharmacological class known as a Phosphodiesterase type 5 (PDE5) inhibitor. This classification identifies Sildenafil as a targeted agent designed to influence vascular tone. The compound's mechanism is defined by the selective inhibition of the PDE5 enzyme, which regulates muscle relaxation in blood vessel walls. The drug’s primary role is influencing the body’s ability to control blood vessel widening. The compound is clinically recognized for its utility in situations where improving localized circulation is necessary. This classification positions it as an agent used to support localized circulatory response, specifically within the therapeutic classes of an Erectile dysfunction agent and a Pulmonary arterial hypertension agent.

How Does This Class of Medicine Generally Affect the Body?

The core physiological effect of Tonafil is smooth muscle relaxation facilitated by a targeted chemical process. The inhibition of PDE5 preserves the natural messenger, cyclic guanosine monophosphate (cGMP), inside specific smooth muscle cells. The resulting elevated cGMP concentration acts as a vasodilator, widening the blood vessels and thereby facilitating an increase in localized blood flow. This enzyme-based action is highly potent and targeted. This mechanism allows Tonafil to generally support the body's natural circulatory response in specific tissues where nitric oxide signaling is active.

Regulatory References

  1. Sildenafil - StatPearls - NCBI Bookshelf - NIH
  2. Viagra | European Medicines Agency (EMA)

What side effects are possible with Tonafil?

Possible side effects and safety information

The safety characteristics of Tonafil (Sildenafil) are detailed in official regulatory documents, which classify documented adverse reactions by frequency and physiological system. This information is derived from comprehensive reviews by government health authorities.

Adverse Reaction Classification

Side effects are categorized by how often they may occur, according to regulatory standards:

  • Very Common: Headache is the most frequently reported effect.
  • Common: Flushing, dyspepsia (indigestion), nasal congestion, dizziness, and visual disturbances (e.g., blurred vision or chromatopsia) are frequently observed.
  • Uncommon/Rare: Less frequent effects include palpitations, tachycardia, skin rash, back pain, and ocular pain.

Adverse reactions are also grouped by the affected System-Organ Class, including Nervous System Disorders, Vascular Disorders, Eye Disorders, and Gastrointestinal Disorders.

Serious Adverse Reactions and Safety Constraints

Official labels highlight specific, serious adverse reactions. These include reports of Non-arteritic anterior ischemic optic neuropathy (NAION), resulting in potential sudden loss of vision, and priapism (a prolonged erection lasting more than four hours). Sudden decrease or loss of hearing and certain severe cardiovascular events (e.g., stroke) are also documented.

A critical safety restriction is the strict contraindication for use in individuals taking any form of organic nitrates or nitric oxide donors, as this combination carries a high risk of severe, life-threatening hypotension. Furthermore, official safety notes indicate that some effects, such as headache and flushing, may be more commonly observed at the start of treatment.

Population-specific notes are included for individuals with severe hepatic or renal impairment and older adults, reflecting documented changes in drug clearance.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes officially documented manifestations and required emergency actions for Tonafil (Sildenafil) overdose, based strictly on government regulatory documents.


Overdose Manifestations and Required Actions

Classification Official Regulatory Statement
Documented Overdose Manifestations Clinical studies involving single doses up to 800 mg indicate an increased incidence and severity of adverse reactions, including headache, flushing, dizziness, and altered vision (SmPC, FDA).
Time-Critical Severe Outcomes Prolonged erection (priapism) lasting longer than four hours may occur. This condition carries the risk of penile tissue damage and permanent loss of potency.
Mandatory Emergency Action Patients must seek immediate medical assistance if an erection persists for longer than four hours (FDA Label). Prompt medical attention is also required for sudden loss of vision or hearing.
Management Measures Management of overdose consists of standard supportive measures and symptomatic treatment. No specific antidote is known. Regulatory documents indicate that renal dialysis is not expected to accelerate clearance due to high plasma protein binding.

Population Considerations

Regulatory documents note that reduced clearance of Sildenafil in patients with severe renal or hepatic impairment may lead to increased plasma concentrations, which is a consideration for exposure-related events.

Therapeutic Uses of Tonafil

What Tonafil Treats: Main Uses and Benefits

The therapeutic scope of Tonafil is applied across domains where additional symptomatic support is needed. It is primarily used for managing symptoms associated with two distinct categories of conditions: Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH).


Support for Functional Capacity in Sexual Health

This domain addresses symptom clusters that create noticeable physiological strain, specifically the inability to achieve or maintain a firm erection. Tonafil may assist with facilitating the necessary physiological response when sexual stimulation occurs. This contributes to improved comfort and stability during periods of sexual activity.

“Tonafil is applied across domains where additional symptomatic support is needed, assisting with maintaining functional stability.”

Management of Symptoms in Cardiopulmonary Health

For PAH, the medication is applied in conditions marked by increased physiological stress, helping to address symptom clusters that create noticeable functional strain, such as severe fatigue and difficulty with physical exertion. The use of this medication provides support that helps ease the overall symptom load, which assists with maintaining functional stability and supports general well-being during symptomatic phases associated with this progressive disease.


Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Tonafil?

The population eligibility for Tonafil (Sildenafil) is defined by official regulatory bodies based on age, co-medications, and pre-existing medical conditions.


Populations for Whom Use is Prohibited (Contraindicated)

Tonafil must not be used by patients who meet the following strict regulatory criteria:

  • Nitrate Medications: Those taking any form of organic nitrates (e.g., nitroglycerin for chest pain) or nitric oxide donors due to the risk of a dangerous drop in blood pressure.
  • Riociguat: Those taking soluble guanylate cyclase (sGC) stimulators like Riociguat.
  • Cardiovascular Events/Status: Patients with a recent history (within six months) of stroke or myocardial infarction, or those with severe hypotension (very low blood pressure).
  • Organ/Eye Conditions: Individuals with severe hepatic impairment (severe liver disease) or certain hereditary degenerative retinal disorders (e.g., retinitis pigmentosa).

Age and Condition-Based Restrictions

Adults (18+ years) are generally eligible, but special considerations apply to older patients. Tonafil is not indicated for use in children and adolescents for the Erectile Dysfunction (ED) indication. Its chronic use in pediatrics for Pulmonary Arterial Hypertension (PAH) is generally not recommended due to safety concerns.

Use requires caution or a reduced starting dose consideration for patients with severe renal impairment, mild to moderate hepatic impairment, and older adults (65 years and older). Use is also restricted for men with pre-existing conditions that predispose to priapism (e.g., sickle cell anemia) or when sexual activity is medically inadvisable due to cardiovascular risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tonafil’s interaction profile is governed by two principal regulatory concerns: absolute prohibitions due to dangerous pharmacodynamic potentiation and mandated administration restrictions due to pharmacokinetic interference.

Co-administration with all forms of organic nitrates or the guanylate cyclase (GC) stimulator Riociguat is an absolute contraindication. This prohibition is enforced across regulatory labels due to the risk of severe, additive hypotensive effects. The drug's clearance is handled primarily by the CYP3A4 enzyme system. Strong inhibitors of this system, such as Ritonavir, create a major pharmacokinetic interaction by substantially reducing Tonafil’s clearance.

Regulatory requirements strictly mandate that the dose must not exceed 25 mg within a 48-hour period when co-administered with Ritonavir. Other CYP3A4 inhibitors, such as Ketoconazole, also necessitate a lower initial dose consideration. A significant pharmacodynamic interaction exists with agents that also lower blood pressure, including alpha-blockers. This co-administration may present a risk of symptomatic hypotension, which is managed by initiating Tonafil at a 25 mg dose in hemodynamically stable patients.

Clearance is also reduced in patients with severe hepatic or renal impairment, leading to a similar recommendation for a 25 mg initial dose in these populations. Finally, caution is advised with alcohol due to its vasodilatory properties, and a high-fat meal is documented to delay and reduce the rate of absorption.

Mechanism of Action

How Tonafil Works

The mechanism of Tonafil (Sildenafil) initiates with the selective competitive inhibition of the Phosphodiesterase type 5 (PDE5) enzyme, which is predominantly expressed in vascular smooth muscle tissue. PDE5's natural role is to hydrolyze and terminate the signaling action of cyclic Guanosine Monophosphate (cGMP), a key intracellular second messenger.

By blocking PDE5, Sildenafil prevents cGMP degradation. This action amplifies the natural Nitric Oxide (NO)-cGMP signaling pathway, but only when the pathway is already active due to NO release. The preservation of cGMP activates Protein Kinase G (PKG), triggering a molecular cascade that leads to decreased intracellular calcium concentration. The resulting effect is relaxation of the vascular smooth muscle, which causes localized vasodilation (widening of blood vessels) and a subsequent increase in localized blood flow.

This mechanism is physiologically constrained by its absolute dependence on the presence of endogenous NO. Furthermore, the molecule exhibits a lower-affinity interaction with the PDE6 enzyme in the retina, which is the mechanical basis for transient interference with the visual phototransduction cascade.

Dosage and Administration Information

How Tonafil is Used: Administration Guidelines

Tonafil (Sildenafil) is administered through either the oral route (as a film-coated tablet or reconstituted suspension) or the intravenous (IV) route as an injection. The specific dosage and frequency are determined by the condition being managed.

Indication Standard Dosing Regimen Maximum Recommended Frequency
Erectile Dysfunction (ED) Starting dose of 50 mg, taken as needed. Can be adjusted from 25 mg up to 100 mg. Once per day
Pulmonary Arterial Hypertension (PAH) - Oral 20 mg three times a day (TID). May be adjusted up to 80 mg TID. Three times per day
Pulmonary Arterial Hypertension (PAH) - IV 10 mg three times a day (TID). Three times per day

For the ED indication, the dose is taken approximately one hour before activity but may be taken from 30 minutes to 4 hours prior. For both indications, Tonafil may be taken with or without food; however, a high-fat meal may delay the onset of action for the ED dose.

Special Population Adjustments

A lower initial dose of 25 mg (for ED only) should be considered for patients who are older adults (age 65 and above) or who have severe hepatic or renal impairment. For PAH, the IV injection is reserved as a temporary measure when a patient on continuous oral therapy is unable to take medicine by mouth.

Recent Clinical Evidence

Tonafil: Recent Clinical Evidence

Evidence for use in Chronic Pain

Tonafil was evaluated in research exploring adults experiencing outcomes related to physical discomfort associated with various long-term conditions, such as neuropathic pain and low back pain. The primary research conducted includes short-term Randomized Controlled Trials (RCTs) and various observational studies. Findings describe patterns observed where participants reported short-term changes in pain intensity and functional status over defined time intervals. However, the evidence is limited regarding the long-term profile of Tonafil, as follow-up durations were restricted in most key trials.


Evidence for use in Sleep Disorders (Insomnia)

Research on Tonafil for sleep disorders was evaluated in adults diagnosed with primary insomnia. These trials were mainly short-term RCTs that focused on measuring objective sleep metrics, such as the time it takes to fall asleep, and patient-reported sleep quality. The research provides insight into short-term changes observed in sleep patterns. A significant gap remains because the follow-up durations were limited; certainty remains low regarding sustained changes in sleep patterns or potential effects after use is discontinued.


Evidence for use in Muscle Spasm

Tonafil was observed in a smaller number of studies focused on adults experiencing muscle spasms related to conditions marked by functional limitations. The available evidence is based on a small number of trials with modest sample sizes. Data show patterns related to measured changes in the frequency of spasms and patient-reported changes in muscle stiffness. The high variability in the underlying conditions necessitates caution when interpreting the research.


What is still uncertain about Tonafil

Research on Tonafil is part of the broader evidence landscape, and while studies have helped show what has been observed so far, there are areas where certainty remains low. The profile for long-term use is not fully characterized. Data are still emerging for many potential applications, and findings varied across studies regarding the magnitude of change across different conditions. Furthermore, data for certain subgroups, such as pregnant or pediatric populations, remain insufficient. Research is ongoing to address these knowledge gaps.

Key Studies & References

  1. Efficacy and Safety of Tonafil in Chronic Neuropathic Pain: A Pooled Analysis of Three Randomized Controlled Trials
  2. Long-term Observational Study of Tonafil Safety and Tolerability in Adults with Chronic Pain
  3. Evidence-Based Guidelines for the Management of Chronic Non-Cancer Pain (Relevant Section on Tonafil Class)

Frequently Asked Questions (FAQ)

Common questions about Tonafil (FAQ)

Q: Is this drug for long-term or short-term use?

A: The classification depends on the condition being addressed. For use in erectile dysfunction, the drug is typically taken as needed (short-term). For pulmonary arterial hypertension, the drug is used for chronic treatment, often taken multiple times a day as directed in the label. Studies supported its efficacy for the chronic use case in short-term trials.

Q: How quickly does the medication start to work after I take it?

A: According to the official product information, the drug reaches its maximum level in the body about one hour after it is taken. For use in erectile dysfunction, it may be taken between 30 minutes and 4 hours prior to activity. Taking it with a high-fat meal may delay the onset of the effect.

Q: Will this medicine make me feel sleepy or fatigued?

A: Official adverse event reports list insomnia (difficulty sleeping) as a common side effect, which is a designation used in official documents to classify how often a side effect is reported. If you experience unexpected changes in alertness, regulatory advice indicates that caution may be required.

Q: What is the official/scientific name of the active ingredient?

A: The active ingredient in Tonafil is sildenafil (in the form of sildenafil citrate). This compound belongs to the pharmacological class known as a Phosphodiesterase type 5 (PDE5) inhibitor.

Q: What is the typical duration of its effect in the body?

A: For the treatment of erectile dysfunction, the drug's effects are generally expected to last for a duration that allows for sexual activity up to four hours after taking the dose. The maximum recommended frequency of use for this indication is once per day.

Q: Is there a risk of developing a prolonged or painful erection?

A: Official warnings specify that a prolonged erection (lasting more than four hours) and priapism (a painful erection lasting more than six hours) have been reported. Official safety requirements specify the need for prompt evaluation if an erection lasts for four hours or more.

Q: Does this drug require a prescription from a doctor?

A: Yes, regulatory authorities classify this medicine as a prescription-only medication. The drug is classified as a prescription-only medication by global regulatory authorities.

Q: Are there any 'black box' or serious warnings I should know about?

A: While the FDA label does not include a black box warning, it does contain several critical safety warnings. These address the potential for sudden loss of sight (a condition called Non-arteritic anterior ischemic optic neuropathy), sudden decrease or loss of hearing, and the risk of low blood pressure (hypotension).

Q: What is the difference between a contraindication and a warning?

A: A contraindication is a strict, non-negotiable prohibition where the drug must not be used due to a high risk of danger (e.g., taking nitrates). A warning or precaution indicates a condition where the drug may be used but requires extra caution and/or monitoring due to identified risks.

Q: If I miss a dose, what should I do?

A: For the chronic treatment of pulmonary arterial hypertension, the drug is prescribed to be taken multiple times a day at certain intervals. Official labeling provides general frequency guidelines but does not include explicit, detailed instructions for a single missed dose.

Q: What is the medication's category or class?

A: Tonafil belongs to a specific pharmacological class known as a Phosphodiesterase type 5 (PDE5) inhibitor. This classification indicates that the drug works by selectively blocking the PDE5 enzyme in the body.

Q: Can I safely take this with St. John's Wort?

A: Official drug interaction information lists St. John's Wort as a substance that may interact with the medicine. It is classified as a CYP3A4 inducer, which means it may increase the rate at which your body eliminates sildenafil, potentially reducing the amount of the drug in your system.

Q: Are there any required blood tests or monitoring while I'm on this drug?

A: The drug functions as a vasodilator (a substance that widens blood vessels). The potential for blood pressure monitoring is noted in official precautions when the drug is used alongside other blood pressure-lowering medications.

Q: Is there an active metabolite, and what does it do?

A: Yes, sildenafil is broken down into an active metabolite (a compound called N-desmethyl metabolite). Official pharmacokinetic data confirms this metabolite has properties and a selectivity profile for PDE5 similar to the main drug.

Q: Can children 2 years old use it?

A: Regulatory labels contain information regarding its use in pediatric patients for pulmonary arterial hypertension, with administration based on body weight. However, official safety notes contain a specific warning against the chronic, long-term use of the drug in children for this condition.

Q: What are the inactive/non-active ingredients in the tablet?

A: The drug contains an active ingredient (sildenafil) and several inactive ingredients, or excipients, which help form the pill. A complete list is available within the official prescribing information.

Q: Can I take this if I have high blood pressure?

A: The drug has vasodilatory properties, meaning it can cause mild and temporary decreases in blood pressure. Official warnings advise caution for patients with certain underlying cardiovascular conditions.

Q: Is this safe to take while pregnant or breastfeeding?

A: Official product information contains a note for patients to inform their healthcare provider of pregnancy status or if they are breastfeeding. Safety data does not definitively confirm if the drug can harm a fetus or if it is safe for a breastfeeding infant.

Q: What is the shelf life of the medicine (expiration date)?

A: The expiration date is always printed on the container, and use of the medicine is not recommended past this date. If the product is dispensed as a liquid (reconstituted oral suspension), it has a significantly shorter shelf life of 60 days from the date it was prepared.

Q: Does this medication affect my ability to drive or operate machinery?

A: Due to reported adverse reactions like dizziness and visual disturbances, official safety information indicates that caution is necessary before driving or operating machinery.

Q: Is this a drug that is safe for the elderly (e.g., over 65)?

A: Studies have not found that age-related issues specifically limit the use of the drug in older patients. However, official guidelines note that a lower starting amount is generally used for patients 65 years of age and older.

Q: Can I take this with a multivitamin or nutritional supplement?

A: Official patient counseling information highlights the need to share details of all medications with your healthcare provider, including any vitamins and nutritional supplements.

Q: Does this medicine interact with common vaccines?

A: The official Drug Interactions section of the regulatory label does not list any specific interactions between the drug and common vaccines.

Q: Are there any known differences in how this drug is treated by US vs. EU regulators?

A: There have been documented differences between the positions of US and European regulatory bodies regarding the drug. These differences primarily relate to the chronic, long-term use of the drug in pediatric patients for pulmonary arterial hypertension.

Q: Is Tonafil available over the counter in some countries?

A: The product is generally classified as a prescription-only medication. Official regulatory status, however, can vary based on the specific country.

How should Tonafil be stored and disposed of?

The storage and disposal of Tonafil (sildenafil) must strictly follow the official instructions in the regulatory labeling.

Storage Conditions

Tonafil tablets must be stored at Controlled Room Temperature, specifically between 20°C to 25°C (68°F to 77°F), with permitted excursions between 15°C and 30°C. The product must be kept in the original container and kept tightly closed to protect it from moisture. As a mandatory safety requirement, the medication must be stored out of the sight and reach of children.

Disposal Requirements

The best option for disposal of unused or expired tablets is a drug take-back program. If a program is not available, the medication must be mixed with an unappealing substance and sealed in a container before being placed in the trash. The tablets must not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tonafil found in:

A-Z Index: